Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Prostate Cancer

  Free Subscription

Articles published in Eur Radiol

Retrieve available abstracts of 63 articles:
HTML format

Single Articles

    November 2023
  1. MA J, Yang Q, Ye X, Xu W, et al
    Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
    Eur Radiol. 2023 Nov 20. doi: 10.1007/s00330-023-10436.
    PubMed     Abstract available

  2. NETZER N, Eith C, Bethge O, Hielscher T, et al
    Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
    Eur Radiol. 2023;33:7463-7476.
    PubMed     Abstract available

    September 2023
  3. COHEN D, Hazut Krauthammer S, Fahoum I, Kesler M, et al
    PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.
    Eur Radiol. 2023;33:6502-6512.
    PubMed     Abstract available

    August 2023
  4. FRANCO PN, Frade-Santos S, Garcia-Baizan A, Paredes-Velazquez L, et al
    An MRI assessment of prostate cancer local recurrence using the PI-RR system: diagnostic accuracy, inter-observer reliability among readers with variable experience, and correlation with PSA values.
    Eur Radiol. 2023 Aug 30. doi: 10.1007/s00330-023-09949.
    PubMed     Abstract available

  5. GRAWE F, Blom F, Winkelmann M, Burgard C, et al
    Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
    Eur Radiol. 2023 Aug 25. doi: 10.1007/s00330-023-10083.
    PubMed     Abstract available

  6. DONNERS R, Tunariu N, Tovey H, Hall E, et al
    The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Eur Radiol. 2023 Aug 24. doi: 10.1007/s00330-023-10172.
    PubMed     Abstract available

  7. MESSINA E, La Torre G, Pecoraro M, Pisciotti ML, et al
    Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
    Eur Radiol. 2023 Aug 10. doi: 10.1007/s00330-023-10019.
    PubMed     Abstract available

  8. MESSINA E, Pecoraro M, Laschena L, Bicchetti M, et al
    Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Eur Radiol. 2023;33:5828-5839.
    PubMed     Abstract available

    July 2023
  9. NHAT TO MN, Kwak JT
    Retraction Note: Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2023 Jul 31. doi: 10.1007/s00330-023-09887.

  10. LIU G, Pan S, Zhao R, Zhou H, et al
    The added value of AI-based computer-aided diagnosis in classification of cancer at prostate MRI.
    Eur Radiol. 2023;33:5118-5130.
    PubMed     Abstract available

  11. JIMENEZ-PASTOR A, Lopez-Gonzalez R, Fos-Guarinos B, Garcia-Castro F, et al
    Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks.
    Eur Radiol. 2023;33:5087-5096.
    PubMed     Abstract available

    May 2023
  12. ASBACH P, Padhani AR
    Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09711.

  13. PADHANI AR, Schoots IG
    Prostate cancer screening-stepping forward with MRI.
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09673.
    PubMed     Abstract available

  14. PUECH P, Gutierrez PA, Berg-Logager V, Villeirs G, et al
    How should we prepare a generation of radiologists for MRI-based prostate cancer screening?
    Eur Radiol. 2023 May 6. doi: 10.1007/s00330-023-09680.

  15. DONSWIJK ML, Piek MW, Cheung Z, Wondergem M, et al
    Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer.
    Eur Radiol. 2023;33:3377-3385.
    PubMed     Abstract available

  16. VEERMAN H, Hagens MJ, Hoeks CM, van der Poel HG, et al
    A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement.
    Eur Radiol. 2023;33:3295-3302.
    PubMed     Abstract available

    April 2023
  17. MARTURANO F, Guglielmo P, Bettinelli A, Zattoni F, et al
    Role of radiomic analysis of [(18)F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging.
    Eur Radiol. 2023 Apr 20. doi: 10.1007/s00330-023-09642.
    PubMed     Abstract available

  18. GAUR S
    Commentary: considering radiomics in the setting of prostate cancer active surveillance.
    Eur Radiol. 2023 Apr 18. doi: 10.1007/s00330-023-09634.

  19. SCHIRO S, Milanese G, Maddalo M, Ziglioli F, et al
    MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models.
    Eur Radiol. 2023;33:2975-2984.
    PubMed     Abstract available

  20. THIMANSSON E, Bengtsson J, Baubeta E, Engman J, et al
    Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI.
    Eur Radiol. 2023;33:2519-2528.
    PubMed     Abstract available

  21. PARK MY, Park KJ, Kim MH, Kim JK, et al
    Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value.
    Eur Radiol. 2023;33:2985-2994.
    PubMed     Abstract available

    March 2023
  22. QIN C, Goldberg O, Kakar G, Wan S, et al
    MRI fat fraction imaging of nodal and bone metastases in prostate cancer.
    Eur Radiol. 2023 Mar 16. doi: 10.1007/s00330-023-09527.
    PubMed     Abstract available

  23. BAUCKNEHT M, Miceli A, Signori A, Albano D, et al
    Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
    Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
    PubMed     Abstract available

    February 2023
  24. SUSHENTSEV N, Rundo L, Abrego L, Li Z, et al
    Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2023 Feb 7. doi: 10.1007/s00330-023-09438.
    PubMed     Abstract available

    January 2023
  25. LABUS S, Altmann MM, Huisman H, Tong A, et al
    A concurrent, deep learning-based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists.
    Eur Radiol. 2023;33:64-76.
    PubMed     Abstract available

  26. GIGANTI F, Cole AP, Fennessy FM, Clinton T, et al
    Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
    Eur Radiol. 2023;33:461-471.
    PubMed     Abstract available

    November 2022
  27. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
    Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Eur Radiol. 2022;32:7544-7554.
    PubMed     Abstract available

  28. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    PubMed     Abstract available

    October 2022
  29. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    PubMed     Abstract available

    September 2022
  30. GANDAGLIA G, Giannarini G, Stabile A, Montorsi F, et al
    Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer.
    Eur Radiol. 2022 Sep 15. pii: 10.1007/s00330-022-09096.

  31. PANEBIANCO V, Turkbey B
    Magnetic resonance imaging for prostate cancer recurrence: it's time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score.
    Eur Radiol. 2022 Sep 1. pii: 10.1007/s00330-022-09095.

    August 2022
  32. ROEST C, Kwee TC, Saha A, Futterer JJ, et al
    AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study.
    Eur Radiol. 2022 Aug 12. pii: 10.1007/s00330-022-09032.
    PubMed     Abstract available

  33. RUD E, Noor D, Galtung KF, Ottosson F, et al
    Validating the screening criteria for bone metastases in treatment-naive unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Eur Radiol. 2022 Aug 8. pii: 10.1007/s00330-022-08945.
    PubMed     Abstract available

    July 2022
  34. DONNERS R, Fotiadis N, Figueiredo I, Blackledge M, et al
    Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Eur Radiol. 2022 Jul 26. pii: 10.1007/s00330-022-09011.
    PubMed     Abstract available

  35. BEHESHTI M, Taimen P, Kemppainen J, Jambor I, et al
    Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Eur Radiol. 2022 Jul 21. pii: 10.1007/s00330-022-08982.
    PubMed     Abstract available

  36. HAMZAOUI D, Montagne S, Granger B, Allera A, et al
    Prostate volume prediction on MRI: tools, accuracy and variability.
    Eur Radiol. 2022;32:4931-4941.
    PubMed     Abstract available

    June 2022
  37. SUSHENTSEV N, McLean MA, Warren AY, Brodie C, et al
    The potential of hyperpolarised (13)C-MRI to target glycolytic tumour core in prostate cancer.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08929.
    PubMed     Abstract available

    May 2022
  38. TO MNN, Kwak JT
    Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08808.
    PubMed     Abstract available

    April 2022
  39. MA W, Mao J, Yang J, Wang T, et al
    Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 29. pii: 10.1007/s00330-022-08802.
    PubMed     Abstract available

  40. BLEKER J, Kwee TC, Rouw D, Roest C, et al
    A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics.
    Eur Radiol. 2022 Apr 14. pii: 10.1007/s00330-022-08712.
    PubMed     Abstract available

  41. PADHANI AR, Haider MA, Rouviere O
    Balancing the benefits and harms of MRI-directed biopsy pathways.
    Eur Radiol. 2022;32:2326-2329.
    PubMed     Abstract available

  42. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.
    Eur Radiol. 2022;32:2372-2383.
    PubMed     Abstract available

    March 2022
  43. GATTI M, Faletti R, Gentile F, Soncin E, et al
    mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging.
    Eur Radiol. 2022 Mar 15. pii: 10.1007/s00330-022-08595.
    PubMed     Abstract available

  44. ZHENG H, Miao Q, Liu Y, Mirak SA, et al
    Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
    Eur Radiol. 2022 Mar 3. pii: 10.1007/s00330-022-08625.
    PubMed     Abstract available

    February 2022
  45. PENZKOFER T, Padhani AR, Turkbey B, Ahmed HU, et al
    Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI.
    Eur Radiol. 2022 Feb 23. pii: 10.1007/s00330-022-08609.

  46. DE ROOIJ M, Barentsz JO
    PI-QUAL v.1: the first step towards good-quality prostate MRI.
    Eur Radiol. 2022;32:876-878.
    PubMed     Abstract available

  47. GIGANTI F, Dinneen E, Kasivisvanathan V, Haider A, et al
    Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
    Eur Radiol. 2022;32:879-889.
    PubMed     Abstract available

    January 2022
  48. BITTENCOURT LK, Guricova K, Zucker I, Durieux JC, et al
    Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study.
    Eur Radiol. 2022 Jan 14. pii: 10.1007/s00330-021-08407.
    PubMed     Abstract available

    December 2021
  49. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.
    Eur Radiol. 2021 Dec 16. pii: 10.1007/s00330-021-08394.
    PubMed     Abstract available

    November 2021
  50. HOSSEINZADEH M, Saha A, Brand P, Slootweg I, et al
    Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.
    Eur Radiol. 2021 Nov 16. pii: 10.1007/s00330-021-08320.
    PubMed     Abstract available

  51. BOSCHHEIDGEN M, Schimmoller L, Arsov C, Ziayee F, et al
    MRI grading for the prediction of prostate cancer aggressiveness.
    Eur Radiol. 2021 Nov 8. pii: 10.1007/s00330-021-08332.
    PubMed     Abstract available

    October 2021
  52. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    PubMed     Abstract available

    September 2021
  53. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    PubMed     Abstract available

  54. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    PubMed     Abstract available

    August 2021
  55. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    PubMed     Abstract available

    July 2021
  56. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    PubMed     Abstract available

  57. BURA V, Caglic I, Snoj Z, Sushentsev N, et al
    MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
    Eur Radiol. 2021;31:4908-4917.
    PubMed     Abstract available

    May 2021
  58. PENZKOFER T, Padhani AR, Turkbey B, Haider MA, et al
    ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.
    Eur Radiol. 2021 May 15. pii: 10.1007/s00330-021-08021.
    PubMed     Abstract available

    April 2021
  59. WALLSTROM J, Geterud K, Kohestani K, Maier SE, et al
    Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial.
    Eur Radiol. 2021 Apr 23. pii: 10.1007/s00330-021-07907.
    PubMed     Abstract available

  60. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    PubMed     Abstract available

    January 2021
  61. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    PubMed     Abstract available

  62. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    PubMed     Abstract available

    November 2020
  63. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.